nodes	percent_of_prediction	percent_of_DWPC	metapath
Pimecrolimus—MTOR—prostate gland—urinary bladder cancer	0.0159	0.084	CbGeAlD
Pimecrolimus—FKBP1A—prostate gland—urinary bladder cancer	0.0143	0.0756	CbGeAlD
Pimecrolimus—MTOR—seminal vesicle—urinary bladder cancer	0.0134	0.0711	CbGeAlD
Pimecrolimus—CYP3A4—urine—urinary bladder cancer	0.013	0.0688	CbGeAlD
Pimecrolimus—FKBP1A—seminal vesicle—urinary bladder cancer	0.0121	0.0639	CbGeAlD
Pimecrolimus—MTOR—epithelium—urinary bladder cancer	0.0117	0.0617	CbGeAlD
Pimecrolimus—MTOR—smooth muscle tissue—urinary bladder cancer	0.0113	0.0595	CbGeAlD
Pimecrolimus—MTOR—renal system—urinary bladder cancer	0.0108	0.0573	CbGeAlD
Pimecrolimus—FKBP1A—epithelium—urinary bladder cancer	0.0105	0.0555	CbGeAlD
Pimecrolimus—FKBP1A—smooth muscle tissue—urinary bladder cancer	0.0101	0.0535	CbGeAlD
Pimecrolimus—FKBP1A—renal system—urinary bladder cancer	0.00975	0.0515	CbGeAlD
Pimecrolimus—FKBP1A—urethra—urinary bladder cancer	0.00957	0.0506	CbGeAlD
Pimecrolimus—MTOR—female reproductive system—urinary bladder cancer	0.00868	0.0459	CbGeAlD
Pimecrolimus—MTOR—vagina—urinary bladder cancer	0.00785	0.0415	CbGeAlD
Pimecrolimus—FKBP1A—female reproductive system—urinary bladder cancer	0.00781	0.0412	CbGeAlD
Pimecrolimus—FKBP1A—vagina—urinary bladder cancer	0.00706	0.0373	CbGeAlD
Pimecrolimus—MTOR—lymph node—urinary bladder cancer	0.00508	0.0268	CbGeAlD
Pimecrolimus—FKBP1A—lymph node—urinary bladder cancer	0.00457	0.0241	CbGeAlD
Pimecrolimus—CYP3A4—renal system—urinary bladder cancer	0.00319	0.0168	CbGeAlD
Pimecrolimus—CYP3A4—female reproductive system—urinary bladder cancer	0.00255	0.0135	CbGeAlD
Pimecrolimus—Nervous system disorder—Thiotepa—urinary bladder cancer	0.000909	0.00206	CcSEcCtD
Pimecrolimus—Skin disorder—Thiotepa—urinary bladder cancer	0.0009	0.00204	CcSEcCtD
Pimecrolimus—Erythema—Cisplatin—urinary bladder cancer	0.00089	0.00201	CcSEcCtD
Pimecrolimus—Malnutrition—Cisplatin—urinary bladder cancer	0.00089	0.00201	CcSEcCtD
Pimecrolimus—Eye disorder—Etoposide—urinary bladder cancer	0.000876	0.00198	CcSEcCtD
Pimecrolimus—Flushing—Etoposide—urinary bladder cancer	0.00087	0.00197	CcSEcCtD
Pimecrolimus—Dermatitis exfoliative—Methotrexate—urinary bladder cancer	0.00086	0.00194	CcSEcCtD
Pimecrolimus—Immune system disorder—Etoposide—urinary bladder cancer	0.000846	0.00191	CcSEcCtD
Pimecrolimus—Mediastinal disorder—Etoposide—urinary bladder cancer	0.000845	0.00191	CcSEcCtD
Pimecrolimus—Musculoskeletal discomfort—Thiotepa—urinary bladder cancer	0.000844	0.00191	CcSEcCtD
Pimecrolimus—Cough—Gemcitabine—urinary bladder cancer	0.000834	0.00188	CcSEcCtD
Pimecrolimus—Paraesthesia—Thiotepa—urinary bladder cancer	0.000832	0.00188	CcSEcCtD
Pimecrolimus—Arthralgia—Gemcitabine—urinary bladder cancer	0.000813	0.00184	CcSEcCtD
Pimecrolimus—Unspecified disorder of skin and subcutaneous tissue—Gemcitabine—urinary bladder cancer	0.000808	0.00183	CcSEcCtD
Pimecrolimus—Dermatitis exfoliative—Epirubicin—urinary bladder cancer	0.000805	0.00182	CcSEcCtD
Pimecrolimus—Gastrointestinal disorder—Thiotepa—urinary bladder cancer	0.0008	0.00181	CcSEcCtD
Pimecrolimus—Constipation—Thiotepa—urinary bladder cancer	0.000793	0.00179	CcSEcCtD
Pimecrolimus—Pain—Thiotepa—urinary bladder cancer	0.000793	0.00179	CcSEcCtD
Pimecrolimus—Back pain—Etoposide—urinary bladder cancer	0.000789	0.00178	CcSEcCtD
Pimecrolimus—Anaphylactic shock—Gemcitabine—urinary bladder cancer	0.00078	0.00176	CcSEcCtD
Pimecrolimus—Oedema—Gemcitabine—urinary bladder cancer	0.00078	0.00176	CcSEcCtD
Pimecrolimus—Infection—Gemcitabine—urinary bladder cancer	0.000775	0.00175	CcSEcCtD
Pimecrolimus—Oedema—Fluorouracil—urinary bladder cancer	0.000767	0.00173	CcSEcCtD
Pimecrolimus—Anaphylactic shock—Fluorouracil—urinary bladder cancer	0.000767	0.00173	CcSEcCtD
Pimecrolimus—Nervous system disorder—Gemcitabine—urinary bladder cancer	0.000765	0.00173	CcSEcCtD
Pimecrolimus—Infection—Fluorouracil—urinary bladder cancer	0.000762	0.00172	CcSEcCtD
Pimecrolimus—Gastrointestinal pain—Thiotepa—urinary bladder cancer	0.000758	0.00171	CcSEcCtD
Pimecrolimus—Skin disorder—Gemcitabine—urinary bladder cancer	0.000757	0.00171	CcSEcCtD
Pimecrolimus—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—urinary bladder cancer	0.000753	0.0017	CcSEcCtD
Pimecrolimus—Nervous system disorder—Fluorouracil—urinary bladder cancer	0.000752	0.0017	CcSEcCtD
Pimecrolimus—Dermatitis exfoliative—Doxorubicin—urinary bladder cancer	0.000745	0.00168	CcSEcCtD
Pimecrolimus—Urticaria—Thiotepa—urinary bladder cancer	0.000736	0.00166	CcSEcCtD
Pimecrolimus—Breast disorder—Methotrexate—urinary bladder cancer	0.000733	0.00166	CcSEcCtD
Pimecrolimus—Face oedema—Epirubicin—urinary bladder cancer	0.000733	0.00166	CcSEcCtD
Pimecrolimus—Abdominal pain—Thiotepa—urinary bladder cancer	0.000733	0.00166	CcSEcCtD
Pimecrolimus—Body temperature increased—Thiotepa—urinary bladder cancer	0.000733	0.00166	CcSEcCtD
Pimecrolimus—Anaphylactic shock—Cisplatin—urinary bladder cancer	0.000727	0.00164	CcSEcCtD
Pimecrolimus—Oedema—Cisplatin—urinary bladder cancer	0.000727	0.00164	CcSEcCtD
Pimecrolimus—Infection—Cisplatin—urinary bladder cancer	0.000722	0.00163	CcSEcCtD
Pimecrolimus—Nervous system disorder—Cisplatin—urinary bladder cancer	0.000713	0.00161	CcSEcCtD
Pimecrolimus—Cough—Etoposide—urinary bladder cancer	0.000712	0.00161	CcSEcCtD
Pimecrolimus—Musculoskeletal discomfort—Gemcitabine—urinary bladder cancer	0.00071	0.00161	CcSEcCtD
Pimecrolimus—Skin disorder—Cisplatin—urinary bladder cancer	0.000706	0.0016	CcSEcCtD
Pimecrolimus—Asthma—Methotrexate—urinary bladder cancer	0.000701	0.00159	CcSEcCtD
Pimecrolimus—Paraesthesia—Gemcitabine—urinary bladder cancer	0.0007	0.00158	CcSEcCtD
Pimecrolimus—Musculoskeletal discomfort—Fluorouracil—urinary bladder cancer	0.000698	0.00158	CcSEcCtD
Pimecrolimus—Dyspnoea—Gemcitabine—urinary bladder cancer	0.000695	0.00157	CcSEcCtD
Pimecrolimus—Abdominal pain upper—Epirubicin—urinary bladder cancer	0.000694	0.00157	CcSEcCtD
Pimecrolimus—Unspecified disorder of skin and subcutaneous tissue—Etoposide—urinary bladder cancer	0.00069	0.00156	CcSEcCtD
Pimecrolimus—Paraesthesia—Fluorouracil—urinary bladder cancer	0.000688	0.00156	CcSEcCtD
Pimecrolimus—Breast disorder—Epirubicin—urinary bladder cancer	0.000686	0.00155	CcSEcCtD
Pimecrolimus—Dyspnoea—Fluorouracil—urinary bladder cancer	0.000683	0.00155	CcSEcCtD
Pimecrolimus—Hypersensitivity—Thiotepa—urinary bladder cancer	0.000683	0.00154	CcSEcCtD
Pimecrolimus—Nasopharyngitis—Epirubicin—urinary bladder cancer	0.000679	0.00154	CcSEcCtD
Pimecrolimus—Face oedema—Doxorubicin—urinary bladder cancer	0.000678	0.00153	CcSEcCtD
Pimecrolimus—Gastrointestinal disorder—Gemcitabine—urinary bladder cancer	0.000673	0.00152	CcSEcCtD
Pimecrolimus—Pain—Gemcitabine—urinary bladder cancer	0.000667	0.00151	CcSEcCtD
Pimecrolimus—Constipation—Gemcitabine—urinary bladder cancer	0.000667	0.00151	CcSEcCtD
Pimecrolimus—Anaphylactic shock—Etoposide—urinary bladder cancer	0.000666	0.00151	CcSEcCtD
Pimecrolimus—Musculoskeletal discomfort—Cisplatin—urinary bladder cancer	0.000662	0.0015	CcSEcCtD
Pimecrolimus—Gastrointestinal disorder—Fluorouracil—urinary bladder cancer	0.000662	0.0015	CcSEcCtD
Pimecrolimus—Infection—Etoposide—urinary bladder cancer	0.000661	0.0015	CcSEcCtD
Pimecrolimus—Asthma—Epirubicin—urinary bladder cancer	0.000656	0.00148	CcSEcCtD
Pimecrolimus—Influenza—Epirubicin—urinary bladder cancer	0.000656	0.00148	CcSEcCtD
Pimecrolimus—Pruritus—Thiotepa—urinary bladder cancer	0.000656	0.00148	CcSEcCtD
Pimecrolimus—Pain—Fluorouracil—urinary bladder cancer	0.000656	0.00148	CcSEcCtD
Pimecrolimus—Paraesthesia—Cisplatin—urinary bladder cancer	0.000653	0.00148	CcSEcCtD
Pimecrolimus—Upper respiratory tract infection—Methotrexate—urinary bladder cancer	0.000652	0.00147	CcSEcCtD
Pimecrolimus—Dyspnoea—Cisplatin—urinary bladder cancer	0.000648	0.00146	CcSEcCtD
Pimecrolimus—Skin disorder—Etoposide—urinary bladder cancer	0.000647	0.00146	CcSEcCtD
Pimecrolimus—Abdominal pain upper—Doxorubicin—urinary bladder cancer	0.000642	0.00145	CcSEcCtD
Pimecrolimus—Photosensitivity reaction—Methotrexate—urinary bladder cancer	0.00064	0.00145	CcSEcCtD
Pimecrolimus—Breast disorder—Doxorubicin—urinary bladder cancer	0.000635	0.00144	CcSEcCtD
Pimecrolimus—Diarrhoea—Thiotepa—urinary bladder cancer	0.000634	0.00143	CcSEcCtD
Pimecrolimus—Bronchitis—Epirubicin—urinary bladder cancer	0.000631	0.00143	CcSEcCtD
Pimecrolimus—Pneumonia—Methotrexate—urinary bladder cancer	0.000629	0.00142	CcSEcCtD
Pimecrolimus—Nasopharyngitis—Doxorubicin—urinary bladder cancer	0.000628	0.00142	CcSEcCtD
Pimecrolimus—Gastrointestinal disorder—Cisplatin—urinary bladder cancer	0.000627	0.00142	CcSEcCtD
Pimecrolimus—Infestation NOS—Methotrexate—urinary bladder cancer	0.000625	0.00141	CcSEcCtD
Pimecrolimus—Infestation—Methotrexate—urinary bladder cancer	0.000625	0.00141	CcSEcCtD
Pimecrolimus—Pain—Cisplatin—urinary bladder cancer	0.000621	0.00141	CcSEcCtD
Pimecrolimus—Body temperature increased—Gemcitabine—urinary bladder cancer	0.000616	0.00139	CcSEcCtD
Pimecrolimus—Upper respiratory tract infection—Epirubicin—urinary bladder cancer	0.00061	0.00138	CcSEcCtD
Pimecrolimus—Urticaria—Fluorouracil—urinary bladder cancer	0.000609	0.00138	CcSEcCtD
Pimecrolimus—Conjunctivitis—Methotrexate—urinary bladder cancer	0.000608	0.00137	CcSEcCtD
Pimecrolimus—Asthma—Doxorubicin—urinary bladder cancer	0.000607	0.00137	CcSEcCtD
Pimecrolimus—Influenza—Doxorubicin—urinary bladder cancer	0.000607	0.00137	CcSEcCtD
Pimecrolimus—Body temperature increased—Fluorouracil—urinary bladder cancer	0.000606	0.00137	CcSEcCtD
Pimecrolimus—Photosensitivity reaction—Epirubicin—urinary bladder cancer	0.000599	0.00135	CcSEcCtD
Pimecrolimus—Paraesthesia—Etoposide—urinary bladder cancer	0.000598	0.00135	CcSEcCtD
Pimecrolimus—Dyspnoea—Etoposide—urinary bladder cancer	0.000594	0.00134	CcSEcCtD
Pimecrolimus—Epistaxis—Methotrexate—urinary bladder cancer	0.00059	0.00133	CcSEcCtD
Pimecrolimus—Vomiting—Thiotepa—urinary bladder cancer	0.000589	0.00133	CcSEcCtD
Pimecrolimus—Pneumonia—Epirubicin—urinary bladder cancer	0.000589	0.00133	CcSEcCtD
Pimecrolimus—Infestation NOS—Epirubicin—urinary bladder cancer	0.000585	0.00132	CcSEcCtD
Pimecrolimus—Infestation—Epirubicin—urinary bladder cancer	0.000585	0.00132	CcSEcCtD
Pimecrolimus—Rash—Thiotepa—urinary bladder cancer	0.000584	0.00132	CcSEcCtD
Pimecrolimus—Bronchitis—Doxorubicin—urinary bladder cancer	0.000584	0.00132	CcSEcCtD
Pimecrolimus—Dermatitis—Thiotepa—urinary bladder cancer	0.000584	0.00132	CcSEcCtD
Pimecrolimus—Headache—Thiotepa—urinary bladder cancer	0.000581	0.00131	CcSEcCtD
Pimecrolimus—Gastrointestinal disorder—Etoposide—urinary bladder cancer	0.000575	0.0013	CcSEcCtD
Pimecrolimus—Body temperature increased—Cisplatin—urinary bladder cancer	0.000575	0.0013	CcSEcCtD
Pimecrolimus—Pain—Etoposide—urinary bladder cancer	0.000569	0.00129	CcSEcCtD
Pimecrolimus—Constipation—Etoposide—urinary bladder cancer	0.000569	0.00129	CcSEcCtD
Pimecrolimus—Conjunctivitis—Epirubicin—urinary bladder cancer	0.000569	0.00129	CcSEcCtD
Pimecrolimus—Hypersensitivity—Fluorouracil—urinary bladder cancer	0.000565	0.00128	CcSEcCtD
Pimecrolimus—Upper respiratory tract infection—Doxorubicin—urinary bladder cancer	0.000564	0.00128	CcSEcCtD
Pimecrolimus—Pharyngitis—Methotrexate—urinary bladder cancer	0.000557	0.00126	CcSEcCtD
Pimecrolimus—Photosensitivity reaction—Doxorubicin—urinary bladder cancer	0.000554	0.00125	CcSEcCtD
Pimecrolimus—Epistaxis—Epirubicin—urinary bladder cancer	0.000552	0.00125	CcSEcCtD
Pimecrolimus—Pruritus—Gemcitabine—urinary bladder cancer	0.000552	0.00125	CcSEcCtD
Pimecrolimus—Nausea—Thiotepa—urinary bladder cancer	0.000551	0.00124	CcSEcCtD
Pimecrolimus—Sinusitis—Epirubicin—urinary bladder cancer	0.000549	0.00124	CcSEcCtD
Pimecrolimus—Pneumonia—Doxorubicin—urinary bladder cancer	0.000545	0.00123	CcSEcCtD
Pimecrolimus—Gastrointestinal pain—Etoposide—urinary bladder cancer	0.000544	0.00123	CcSEcCtD
Pimecrolimus—Pruritus—Fluorouracil—urinary bladder cancer	0.000542	0.00123	CcSEcCtD
Pimecrolimus—Infestation NOS—Doxorubicin—urinary bladder cancer	0.000541	0.00122	CcSEcCtD
Pimecrolimus—Infestation—Doxorubicin—urinary bladder cancer	0.000541	0.00122	CcSEcCtD
Pimecrolimus—Hypersensitivity—Cisplatin—urinary bladder cancer	0.000535	0.00121	CcSEcCtD
Pimecrolimus—Diarrhoea—Gemcitabine—urinary bladder cancer	0.000533	0.00121	CcSEcCtD
Pimecrolimus—Urticaria—Etoposide—urinary bladder cancer	0.000529	0.0012	CcSEcCtD
Pimecrolimus—Rhinitis—Epirubicin—urinary bladder cancer	0.000527	0.00119	CcSEcCtD
Pimecrolimus—Abdominal pain—Etoposide—urinary bladder cancer	0.000526	0.00119	CcSEcCtD
Pimecrolimus—Body temperature increased—Etoposide—urinary bladder cancer	0.000526	0.00119	CcSEcCtD
Pimecrolimus—Conjunctivitis—Doxorubicin—urinary bladder cancer	0.000526	0.00119	CcSEcCtD
Pimecrolimus—Eye disorder—Methotrexate—urinary bladder cancer	0.000525	0.00119	CcSEcCtD
Pimecrolimus—Diarrhoea—Fluorouracil—urinary bladder cancer	0.000525	0.00119	CcSEcCtD
Pimecrolimus—Pharyngitis—Epirubicin—urinary bladder cancer	0.000521	0.00118	CcSEcCtD
Pimecrolimus—Epistaxis—Doxorubicin—urinary bladder cancer	0.000511	0.00115	CcSEcCtD
Pimecrolimus—Sinusitis—Doxorubicin—urinary bladder cancer	0.000508	0.00115	CcSEcCtD
Pimecrolimus—Immune system disorder—Methotrexate—urinary bladder cancer	0.000507	0.00115	CcSEcCtD
Pimecrolimus—Mediastinal disorder—Methotrexate—urinary bladder cancer	0.000506	0.00114	CcSEcCtD
Pimecrolimus—Diarrhoea—Cisplatin—urinary bladder cancer	0.000497	0.00112	CcSEcCtD
Pimecrolimus—Vomiting—Gemcitabine—urinary bladder cancer	0.000496	0.00112	CcSEcCtD
Pimecrolimus—Rash—Gemcitabine—urinary bladder cancer	0.000492	0.00111	CcSEcCtD
Pimecrolimus—Dermatitis—Gemcitabine—urinary bladder cancer	0.000491	0.00111	CcSEcCtD
Pimecrolimus—Eye disorder—Epirubicin—urinary bladder cancer	0.000491	0.00111	CcSEcCtD
Pimecrolimus—Hypersensitivity—Etoposide—urinary bladder cancer	0.000491	0.00111	CcSEcCtD
Pimecrolimus—Malnutrition—Methotrexate—urinary bladder cancer	0.000489	0.0011	CcSEcCtD
Pimecrolimus—Erythema—Methotrexate—urinary bladder cancer	0.000489	0.0011	CcSEcCtD
Pimecrolimus—Headache—Gemcitabine—urinary bladder cancer	0.000488	0.0011	CcSEcCtD
Pimecrolimus—Flushing—Epirubicin—urinary bladder cancer	0.000488	0.0011	CcSEcCtD
Pimecrolimus—Vomiting—Fluorouracil—urinary bladder cancer	0.000487	0.0011	CcSEcCtD
Pimecrolimus—Rhinitis—Doxorubicin—urinary bladder cancer	0.000487	0.0011	CcSEcCtD
Pimecrolimus—Rash—Fluorouracil—urinary bladder cancer	0.000483	0.00109	CcSEcCtD
Pimecrolimus—Dermatitis—Fluorouracil—urinary bladder cancer	0.000483	0.00109	CcSEcCtD
Pimecrolimus—Pharyngitis—Doxorubicin—urinary bladder cancer	0.000482	0.00109	CcSEcCtD
Pimecrolimus—Headache—Fluorouracil—urinary bladder cancer	0.00048	0.00109	CcSEcCtD
Pimecrolimus—Immune system disorder—Epirubicin—urinary bladder cancer	0.000474	0.00107	CcSEcCtD
Pimecrolimus—Mediastinal disorder—Epirubicin—urinary bladder cancer	0.000473	0.00107	CcSEcCtD
Pimecrolimus—Back pain—Methotrexate—urinary bladder cancer	0.000473	0.00107	CcSEcCtD
Pimecrolimus—Pruritus—Etoposide—urinary bladder cancer	0.000471	0.00106	CcSEcCtD
Pimecrolimus—Nausea—Gemcitabine—urinary bladder cancer	0.000463	0.00105	CcSEcCtD
Pimecrolimus—Vomiting—Cisplatin—urinary bladder cancer	0.000462	0.00104	CcSEcCtD
Pimecrolimus—Rash—Cisplatin—urinary bladder cancer	0.000458	0.00104	CcSEcCtD
Pimecrolimus—Dermatitis—Cisplatin—urinary bladder cancer	0.000458	0.00104	CcSEcCtD
Pimecrolimus—Erythema—Epirubicin—urinary bladder cancer	0.000457	0.00103	CcSEcCtD
Pimecrolimus—Malnutrition—Epirubicin—urinary bladder cancer	0.000457	0.00103	CcSEcCtD
Pimecrolimus—Diarrhoea—Etoposide—urinary bladder cancer	0.000456	0.00103	CcSEcCtD
Pimecrolimus—Nausea—Fluorouracil—urinary bladder cancer	0.000455	0.00103	CcSEcCtD
Pimecrolimus—Eye disorder—Doxorubicin—urinary bladder cancer	0.000454	0.00103	CcSEcCtD
Pimecrolimus—Flushing—Doxorubicin—urinary bladder cancer	0.000451	0.00102	CcSEcCtD
Pimecrolimus—Back pain—Epirubicin—urinary bladder cancer	0.000442	0.001	CcSEcCtD
Pimecrolimus—Immune system disorder—Doxorubicin—urinary bladder cancer	0.000439	0.000993	CcSEcCtD
Pimecrolimus—Mediastinal disorder—Doxorubicin—urinary bladder cancer	0.000438	0.00099	CcSEcCtD
Pimecrolimus—Nausea—Cisplatin—urinary bladder cancer	0.000432	0.000976	CcSEcCtD
Pimecrolimus—Cough—Methotrexate—urinary bladder cancer	0.000426	0.000964	CcSEcCtD
Pimecrolimus—Vomiting—Etoposide—urinary bladder cancer	0.000423	0.000957	CcSEcCtD
Pimecrolimus—Erythema—Doxorubicin—urinary bladder cancer	0.000423	0.000957	CcSEcCtD
Pimecrolimus—Malnutrition—Doxorubicin—urinary bladder cancer	0.000423	0.000957	CcSEcCtD
Pimecrolimus—Rash—Etoposide—urinary bladder cancer	0.00042	0.000949	CcSEcCtD
Pimecrolimus—Dermatitis—Etoposide—urinary bladder cancer	0.000419	0.000948	CcSEcCtD
Pimecrolimus—Headache—Etoposide—urinary bladder cancer	0.000417	0.000943	CcSEcCtD
Pimecrolimus—Arthralgia—Methotrexate—urinary bladder cancer	0.000416	0.000941	CcSEcCtD
Pimecrolimus—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—urinary bladder cancer	0.000413	0.000934	CcSEcCtD
Pimecrolimus—Back pain—Doxorubicin—urinary bladder cancer	0.000409	0.000925	CcSEcCtD
Pimecrolimus—Cough—Epirubicin—urinary bladder cancer	0.000399	0.000902	CcSEcCtD
Pimecrolimus—Anaphylactic shock—Methotrexate—urinary bladder cancer	0.000399	0.000902	CcSEcCtD
Pimecrolimus—Infection—Methotrexate—urinary bladder cancer	0.000396	0.000896	CcSEcCtD
Pimecrolimus—Nausea—Etoposide—urinary bladder cancer	0.000395	0.000894	CcSEcCtD
Pimecrolimus—Nervous system disorder—Methotrexate—urinary bladder cancer	0.000391	0.000884	CcSEcCtD
Pimecrolimus—Arthralgia—Epirubicin—urinary bladder cancer	0.000389	0.00088	CcSEcCtD
Pimecrolimus—Skin disorder—Methotrexate—urinary bladder cancer	0.000387	0.000876	CcSEcCtD
Pimecrolimus—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—urinary bladder cancer	0.000387	0.000874	CcSEcCtD
Pimecrolimus—Anaphylactic shock—Epirubicin—urinary bladder cancer	0.000373	0.000844	CcSEcCtD
Pimecrolimus—Oedema—Epirubicin—urinary bladder cancer	0.000373	0.000844	CcSEcCtD
Pimecrolimus—Infection—Epirubicin—urinary bladder cancer	0.000371	0.000838	CcSEcCtD
Pimecrolimus—Cough—Doxorubicin—urinary bladder cancer	0.000369	0.000835	CcSEcCtD
Pimecrolimus—Nervous system disorder—Epirubicin—urinary bladder cancer	0.000366	0.000827	CcSEcCtD
Pimecrolimus—Musculoskeletal discomfort—Methotrexate—urinary bladder cancer	0.000363	0.000821	CcSEcCtD
Pimecrolimus—Skin disorder—Epirubicin—urinary bladder cancer	0.000363	0.00082	CcSEcCtD
Pimecrolimus—Arthralgia—Doxorubicin—urinary bladder cancer	0.00036	0.000814	CcSEcCtD
Pimecrolimus—Paraesthesia—Methotrexate—urinary bladder cancer	0.000358	0.00081	CcSEcCtD
Pimecrolimus—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—urinary bladder cancer	0.000358	0.000809	CcSEcCtD
Pimecrolimus—Dyspnoea—Methotrexate—urinary bladder cancer	0.000356	0.000804	CcSEcCtD
Pimecrolimus—Anaphylactic shock—Doxorubicin—urinary bladder cancer	0.000345	0.000781	CcSEcCtD
Pimecrolimus—Oedema—Doxorubicin—urinary bladder cancer	0.000345	0.000781	CcSEcCtD
Pimecrolimus—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	0.000344	0.000778	CcSEcCtD
Pimecrolimus—Infection—Doxorubicin—urinary bladder cancer	0.000343	0.000776	CcSEcCtD
Pimecrolimus—Pain—Methotrexate—urinary bladder cancer	0.000341	0.000771	CcSEcCtD
Pimecrolimus—Musculoskeletal discomfort—Epirubicin—urinary bladder cancer	0.00034	0.000769	CcSEcCtD
Pimecrolimus—Nervous system disorder—Doxorubicin—urinary bladder cancer	0.000339	0.000766	CcSEcCtD
Pimecrolimus—Skin disorder—Doxorubicin—urinary bladder cancer	0.000335	0.000758	CcSEcCtD
Pimecrolimus—Paraesthesia—Epirubicin—urinary bladder cancer	0.000335	0.000758	CcSEcCtD
Pimecrolimus—Dyspnoea—Epirubicin—urinary bladder cancer	0.000333	0.000752	CcSEcCtD
Pimecrolimus—Gastrointestinal pain—Methotrexate—urinary bladder cancer	0.000326	0.000737	CcSEcCtD
Pimecrolimus—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	0.000322	0.000728	CcSEcCtD
Pimecrolimus—Constipation—Epirubicin—urinary bladder cancer	0.000319	0.000722	CcSEcCtD
Pimecrolimus—Pain—Epirubicin—urinary bladder cancer	0.000319	0.000722	CcSEcCtD
Pimecrolimus—Urticaria—Methotrexate—urinary bladder cancer	0.000317	0.000716	CcSEcCtD
Pimecrolimus—Abdominal pain—Methotrexate—urinary bladder cancer	0.000315	0.000713	CcSEcCtD
Pimecrolimus—Body temperature increased—Methotrexate—urinary bladder cancer	0.000315	0.000713	CcSEcCtD
Pimecrolimus—Musculoskeletal discomfort—Doxorubicin—urinary bladder cancer	0.000315	0.000711	CcSEcCtD
Pimecrolimus—MTOR—Signaling by EGFR—CDKN1A—urinary bladder cancer	0.000313	0.000849	CbGpPWpGaD
Pimecrolimus—MTOR—ErbB1 downstream signaling—HRAS—urinary bladder cancer	0.000312	0.000847	CbGpPWpGaD
Pimecrolimus—MTOR—Senescence and Autophagy in Cancer—HRAS—urinary bladder cancer	0.000312	0.000847	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by EGFR—PTEN—urinary bladder cancer	0.000312	0.000847	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by ERBB2—SRC—urinary bladder cancer	0.000312	0.000847	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by EGFR in Cancer—CDKN1A—urinary bladder cancer	0.00031	0.000842	CbGpPWpGaD
Pimecrolimus—Paraesthesia—Doxorubicin—urinary bladder cancer	0.00031	0.000701	CcSEcCtD
Pimecrolimus—MTOR—Signaling by EGFR in Cancer—PTEN—urinary bladder cancer	0.000309	0.00084	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by PDGF—CDKN1A—urinary bladder cancer	0.000309	0.000838	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by PDGF—PTEN—urinary bladder cancer	0.000308	0.000836	CbGpPWpGaD
Pimecrolimus—Dyspnoea—Doxorubicin—urinary bladder cancer	0.000308	0.000696	CcSEcCtD
Pimecrolimus—MTOR—VEGFA-VEGFR2 Pathway—HRAS—urinary bladder cancer	0.000308	0.000835	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by SCF-KIT—EGFR—urinary bladder cancer	0.000307	0.000834	CbGpPWpGaD
Pimecrolimus—Gastrointestinal pain—Epirubicin—urinary bladder cancer	0.000305	0.00069	CcSEcCtD
Pimecrolimus—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	0.000298	0.000674	CcSEcCtD
Pimecrolimus—MTOR—Integrated Breast Cancer Pathway—MYC—urinary bladder cancer	0.000297	0.000807	CbGpPWpGaD
Pimecrolimus—Urticaria—Epirubicin—urinary bladder cancer	0.000296	0.00067	CcSEcCtD
Pimecrolimus—Constipation—Doxorubicin—urinary bladder cancer	0.000295	0.000668	CcSEcCtD
Pimecrolimus—Pain—Doxorubicin—urinary bladder cancer	0.000295	0.000668	CcSEcCtD
Pimecrolimus—Body temperature increased—Epirubicin—urinary bladder cancer	0.000295	0.000667	CcSEcCtD
Pimecrolimus—Abdominal pain—Epirubicin—urinary bladder cancer	0.000295	0.000667	CcSEcCtD
Pimecrolimus—MTOR—Downstream signaling of activated FGFR—EGFR—urinary bladder cancer	0.000294	0.000798	CbGpPWpGaD
Pimecrolimus—Hypersensitivity—Methotrexate—urinary bladder cancer	0.000294	0.000664	CcSEcCtD
Pimecrolimus—MTOR—Innate Immune System—IFNA2—urinary bladder cancer	0.000293	0.000795	CbGpPWpGaD
Pimecrolimus—MTOR—B Cell Activation—CDKN1A—urinary bladder cancer	0.000292	0.000793	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by FGFR in disease—SRC—urinary bladder cancer	0.000292	0.000793	CbGpPWpGaD
Pimecrolimus—MTOR—B Cell Activation—PTEN—urinary bladder cancer	0.000291	0.000791	CbGpPWpGaD
Pimecrolimus—MTOR—Integrated Breast Cancer Pathway—EGFR—urinary bladder cancer	0.000291	0.000789	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by VEGF—HRAS—urinary bladder cancer	0.00029	0.000788	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by SCF-KIT—KRAS—urinary bladder cancer	0.00029	0.000787	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by EGFR—SRC—urinary bladder cancer	0.000289	0.000786	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by ERBB4—EGFR—urinary bladder cancer	0.000289	0.000785	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by Insulin receptor—HRAS—urinary bladder cancer	0.000288	0.000782	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by EGFR in Cancer—SRC—urinary bladder cancer	0.000287	0.000779	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by PDGF—SRC—urinary bladder cancer	0.000286	0.000775	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—LIG1—urinary bladder cancer	0.000284	0.000771	CbGpPWpGaD
Pimecrolimus—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	0.000282	0.000638	CcSEcCtD
Pimecrolimus—Pruritus—Methotrexate—urinary bladder cancer	0.000282	0.000638	CcSEcCtD
Pimecrolimus—CYP3A4—Biological oxidations—HPGDS—urinary bladder cancer	0.000281	0.000764	CbGpPWpGaD
Pimecrolimus—MTOR—Cellular responses to stress—CDKN2A—urinary bladder cancer	0.000281	0.000761	CbGpPWpGaD
Pimecrolimus—MTOR—NGF signalling via TRKA from the plasma membrane—CDKN1A—urinary bladder cancer	0.00028	0.000759	CbGpPWpGaD
Pimecrolimus—MTOR—NGF signalling via TRKA from the plasma membrane—PTEN—urinary bladder cancer	0.000279	0.000757	CbGpPWpGaD
Pimecrolimus—MTOR—Downstream signaling of activated FGFR—KRAS—urinary bladder cancer	0.000278	0.000753	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—S100B—urinary bladder cancer	0.000277	0.000751	CbGpPWpGaD
Pimecrolimus—MTOR—Downstream signal transduction—EGFR—urinary bladder cancer	0.000276	0.00075	CbGpPWpGaD
Pimecrolimus—Hypersensitivity—Epirubicin—urinary bladder cancer	0.000275	0.000622	CcSEcCtD
Pimecrolimus—MTOR—EGF/EGFR Signaling Pathway—EGFR—urinary bladder cancer	0.000275	0.000746	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by FGFR—EGFR—urinary bladder cancer	0.000275	0.000746	CbGpPWpGaD
Pimecrolimus—MTOR—Integrated Breast Cancer Pathway—KRAS—urinary bladder cancer	0.000275	0.000745	CbGpPWpGaD
Pimecrolimus—Urticaria—Doxorubicin—urinary bladder cancer	0.000274	0.00062	CcSEcCtD
Pimecrolimus—MTOR—Signaling by ERBB2—EGFR—urinary bladder cancer	0.000273	0.000742	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by ERBB4—KRAS—urinary bladder cancer	0.000273	0.000742	CbGpPWpGaD
Pimecrolimus—Abdominal pain—Doxorubicin—urinary bladder cancer	0.000273	0.000617	CcSEcCtD
Pimecrolimus—Body temperature increased—Doxorubicin—urinary bladder cancer	0.000273	0.000617	CcSEcCtD
Pimecrolimus—CYP3A4—Biological oxidations—GSTT1—urinary bladder cancer	0.000273	0.000741	CbGpPWpGaD
Pimecrolimus—Diarrhoea—Methotrexate—urinary bladder cancer	0.000273	0.000617	CcSEcCtD
Pimecrolimus—MTOR—DAP12 signaling—EGFR—urinary bladder cancer	0.000272	0.000739	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by NGF—RHOA—urinary bladder cancer	0.000272	0.000738	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—BIRC3—urinary bladder cancer	0.000271	0.000735	CbGpPWpGaD
Pimecrolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—EGFR—urinary bladder cancer	0.000268	0.000728	CbGpPWpGaD
Pimecrolimus—Pruritus—Epirubicin—urinary bladder cancer	0.000264	0.000597	CcSEcCtD
Pimecrolimus—MTOR—Downstream signal transduction—KRAS—urinary bladder cancer	0.000261	0.000708	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by FGFR—KRAS—urinary bladder cancer	0.00026	0.000705	CbGpPWpGaD
Pimecrolimus—MTOR—EGF/EGFR Signaling Pathway—KRAS—urinary bladder cancer	0.00026	0.000705	CbGpPWpGaD
Pimecrolimus—MTOR—NGF signalling via TRKA from the plasma membrane—SRC—urinary bladder cancer	0.000259	0.000702	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by ERBB2—KRAS—urinary bladder cancer	0.000258	0.000701	CbGpPWpGaD
Pimecrolimus—MTOR—DAP12 signaling—KRAS—urinary bladder cancer	0.000257	0.000698	CbGpPWpGaD
Pimecrolimus—MTOR—Fc epsilon receptor (FCERI) signaling—EGFR—urinary bladder cancer	0.000256	0.000695	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by FGFR in disease—EGFR—urinary bladder cancer	0.000256	0.000695	CbGpPWpGaD
Pimecrolimus—MTOR—DAP12 interactions—EGFR—urinary bladder cancer	0.000256	0.000695	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—RBX1—urinary bladder cancer	0.000256	0.000694	CbGpPWpGaD
Pimecrolimus—Diarrhoea—Epirubicin—urinary bladder cancer	0.000255	0.000577	CcSEcCtD
Pimecrolimus—Hypersensitivity—Doxorubicin—urinary bladder cancer	0.000254	0.000575	CcSEcCtD
Pimecrolimus—MTOR—Cellular responses to stress—CXCL8—urinary bladder cancer	0.000254	0.000691	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by EGFR—EGFR—urinary bladder cancer	0.000254	0.000689	CbGpPWpGaD
Pimecrolimus—Vomiting—Methotrexate—urinary bladder cancer	0.000254	0.000573	CcSEcCtD
Pimecrolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—KRAS—urinary bladder cancer	0.000253	0.000688	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by NGF—ERBB2—urinary bladder cancer	0.000252	0.000683	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by EGFR in Cancer—EGFR—urinary bladder cancer	0.000251	0.000683	CbGpPWpGaD
Pimecrolimus—Rash—Methotrexate—urinary bladder cancer	0.000251	0.000568	CcSEcCtD
Pimecrolimus—Dermatitis—Methotrexate—urinary bladder cancer	0.000251	0.000568	CcSEcCtD
Pimecrolimus—MTOR—Signaling Pathways—HDAC4—urinary bladder cancer	0.00025	0.00068	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by PDGF—EGFR—urinary bladder cancer	0.00025	0.00068	CbGpPWpGaD
Pimecrolimus—Headache—Methotrexate—urinary bladder cancer	0.00025	0.000565	CcSEcCtD
Pimecrolimus—MTOR—Signaling by SCF-KIT—HRAS—urinary bladder cancer	0.000247	0.000669	CbGpPWpGaD
Pimecrolimus—Pruritus—Doxorubicin—urinary bladder cancer	0.000244	0.000552	CcSEcCtD
Pimecrolimus—MTOR—Integrated Breast Cancer Pathway—TP53—urinary bladder cancer	0.000244	0.000663	CbGpPWpGaD
Pimecrolimus—MTOR—BDNF signaling pathway—HRAS—urinary bladder cancer	0.000242	0.000658	CbGpPWpGaD
Pimecrolimus—MTOR—Fc epsilon receptor (FCERI) signaling—KRAS—urinary bladder cancer	0.000242	0.000656	CbGpPWpGaD
Pimecrolimus—MTOR—DAP12 interactions—KRAS—urinary bladder cancer	0.000242	0.000656	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by FGFR in disease—KRAS—urinary bladder cancer	0.000242	0.000656	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—TSC1—urinary bladder cancer	0.00024	0.000653	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by EGFR—KRAS—urinary bladder cancer	0.00024	0.000651	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—NCOR1—urinary bladder cancer	0.000238	0.000646	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by EGFR in Cancer—KRAS—urinary bladder cancer	0.000238	0.000645	CbGpPWpGaD
Pimecrolimus—Vomiting—Epirubicin—urinary bladder cancer	0.000237	0.000536	CcSEcCtD
Pimecrolimus—MTOR—B Cell Activation—EGFR—urinary bladder cancer	0.000237	0.000643	CbGpPWpGaD
Pimecrolimus—Nausea—Methotrexate—urinary bladder cancer	0.000237	0.000536	CcSEcCtD
Pimecrolimus—MTOR—Signaling by PDGF—KRAS—urinary bladder cancer	0.000237	0.000642	CbGpPWpGaD
Pimecrolimus—Diarrhoea—Doxorubicin—urinary bladder cancer	0.000236	0.000534	CcSEcCtD
Pimecrolimus—MTOR—Downstream signaling of activated FGFR—HRAS—urinary bladder cancer	0.000236	0.00064	CbGpPWpGaD
Pimecrolimus—Rash—Epirubicin—urinary bladder cancer	0.000235	0.000532	CcSEcCtD
Pimecrolimus—Dermatitis—Epirubicin—urinary bladder cancer	0.000235	0.000532	CcSEcCtD
Pimecrolimus—Headache—Epirubicin—urinary bladder cancer	0.000234	0.000529	CcSEcCtD
Pimecrolimus—MTOR—Signaling by ERBB4—HRAS—urinary bladder cancer	0.000232	0.00063	CbGpPWpGaD
Pimecrolimus—MTOR—Cellular responses to stress—CDKN1A—urinary bladder cancer	0.000229	0.000622	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—JAG1—urinary bladder cancer	0.000229	0.000621	CbGpPWpGaD
Pimecrolimus—MTOR—NGF signalling via TRKA from the plasma membrane—EGFR—urinary bladder cancer	0.000227	0.000615	CbGpPWpGaD
Pimecrolimus—MTOR—B Cell Activation—KRAS—urinary bladder cancer	0.000224	0.000608	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—ERCC2—urinary bladder cancer	0.000224	0.000607	CbGpPWpGaD
Pimecrolimus—MTOR—Insulin Signaling—HRAS—urinary bladder cancer	0.000223	0.000605	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—RBX1—urinary bladder cancer	0.000222	0.000604	CbGpPWpGaD
Pimecrolimus—MTOR—Downstream signal transduction—HRAS—urinary bladder cancer	0.000222	0.000602	CbGpPWpGaD
Pimecrolimus—Nausea—Epirubicin—urinary bladder cancer	0.000222	0.000501	CcSEcCtD
Pimecrolimus—MTOR—Signaling by FGFR—HRAS—urinary bladder cancer	0.000221	0.000599	CbGpPWpGaD
Pimecrolimus—MTOR—EGF/EGFR Signaling Pathway—HRAS—urinary bladder cancer	0.000221	0.000599	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by ERBB2—HRAS—urinary bladder cancer	0.00022	0.000596	CbGpPWpGaD
Pimecrolimus—Vomiting—Doxorubicin—urinary bladder cancer	0.00022	0.000496	CcSEcCtD
Pimecrolimus—MTOR—DAP12 signaling—HRAS—urinary bladder cancer	0.000219	0.000593	CbGpPWpGaD
Pimecrolimus—MTOR—Cellular responses to stress—EP300—urinary bladder cancer	0.000218	0.000592	CbGpPWpGaD
Pimecrolimus—Rash—Doxorubicin—urinary bladder cancer	0.000218	0.000492	CcSEcCtD
Pimecrolimus—Dermatitis—Doxorubicin—urinary bladder cancer	0.000218	0.000492	CcSEcCtD
Pimecrolimus—MTOR—Disease—ENO2—urinary bladder cancer	0.000217	0.000588	CbGpPWpGaD
Pimecrolimus—Headache—Doxorubicin—urinary bladder cancer	0.000216	0.000489	CcSEcCtD
Pimecrolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—HRAS—urinary bladder cancer	0.000215	0.000585	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by NGF—CDKN1A—urinary bladder cancer	0.000215	0.000584	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by NGF—PTEN—urinary bladder cancer	0.000215	0.000582	CbGpPWpGaD
Pimecrolimus—MTOR—NGF signalling via TRKA from the plasma membrane—KRAS—urinary bladder cancer	0.000214	0.000581	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—MTHFR—urinary bladder cancer	0.00021	0.000571	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—GLI1—urinary bladder cancer	0.00021	0.00057	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—TERT—urinary bladder cancer	0.00021	0.000569	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by FGFR in disease—HRAS—urinary bladder cancer	0.000206	0.000558	CbGpPWpGaD
Pimecrolimus—MTOR—DAP12 interactions—HRAS—urinary bladder cancer	0.000206	0.000558	CbGpPWpGaD
Pimecrolimus—MTOR—Fc epsilon receptor (FCERI) signaling—HRAS—urinary bladder cancer	0.000206	0.000558	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—RBX1—urinary bladder cancer	0.000205	0.000558	CbGpPWpGaD
Pimecrolimus—Nausea—Doxorubicin—urinary bladder cancer	0.000205	0.000464	CcSEcCtD
Pimecrolimus—MTOR—Signaling by EGFR—HRAS—urinary bladder cancer	0.000204	0.000553	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by EGFR in Cancer—HRAS—urinary bladder cancer	0.000202	0.000548	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—FGFR3—urinary bladder cancer	0.000201	0.000546	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by PDGF—HRAS—urinary bladder cancer	0.000201	0.000546	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by NGF—SRC—urinary bladder cancer	0.000199	0.00054	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—FGFR3—urinary bladder cancer	0.000193	0.000525	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—FGFR3—urinary bladder cancer	0.000192	0.000522	CbGpPWpGaD
Pimecrolimus—MTOR—B Cell Activation—HRAS—urinary bladder cancer	0.00019	0.000516	CbGpPWpGaD
Pimecrolimus—CYP3A4—Biological oxidations—GSTP1—urinary bladder cancer	0.000189	0.000514	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metapathway biotransformation—GSTP1—urinary bladder cancer	0.000187	0.000506	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—S100B—urinary bladder cancer	0.000185	0.000503	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—JAG1—urinary bladder cancer	0.000184	0.000499	CbGpPWpGaD
Pimecrolimus—MTOR—NGF signalling via TRKA from the plasma membrane—HRAS—urinary bladder cancer	0.000182	0.000494	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by NGF—EGFR—urinary bladder cancer	0.000174	0.000473	CbGpPWpGaD
Pimecrolimus—CYP3A4—Biological oxidations—GSTM1—urinary bladder cancer	0.000174	0.000472	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metapathway biotransformation—GSTM1—urinary bladder cancer	0.000171	0.000465	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—CREBBP—urinary bladder cancer	0.000171	0.000465	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—IFNA2—urinary bladder cancer	0.000171	0.000463	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—NCOR1—urinary bladder cancer	0.000167	0.000452	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by NGF—KRAS—urinary bladder cancer	0.000165	0.000447	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—CREBBP—urinary bladder cancer	0.000164	0.000445	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—CDH1—urinary bladder cancer	0.000163	0.000443	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—S100B—urinary bladder cancer	0.000161	0.000438	CbGpPWpGaD
Pimecrolimus—MTOR—Cellular responses to stress—TP53—urinary bladder cancer	0.000156	0.000424	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—RHOA—urinary bladder cancer	0.000148	0.000402	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—TERT—urinary bladder cancer	0.000147	0.000399	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—RBX1—urinary bladder cancer	0.000144	0.00039	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—ERBB2—urinary bladder cancer	0.000144	0.00039	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by NGF—HRAS—urinary bladder cancer	0.00014	0.00038	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—ERBB2—urinary bladder cancer	0.000138	0.000374	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—ERBB2—urinary bladder cancer	0.000137	0.000372	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—TSC1—urinary bladder cancer	0.000135	0.000367	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—FGFR3—urinary bladder cancer	0.000135	0.000366	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—PTGS2—urinary bladder cancer	0.000134	0.000364	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—NCOR1—urinary bladder cancer	0.000134	0.000363	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—ESR1—urinary bladder cancer	0.000131	0.000355	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—JAG1—urinary bladder cancer	0.000129	0.000349	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—ERCC2—urinary bladder cancer	0.000126	0.000342	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—CDKN1A—urinary bladder cancer	0.000123	0.000333	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—PTEN—urinary bladder cancer	0.000122	0.000332	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—MTHFR—urinary bladder cancer	0.000118	0.000321	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—TERT—urinary bladder cancer	0.000118	0.00032	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—CDKN1A—urinary bladder cancer	0.000118	0.00032	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—PTEN—urinary bladder cancer	0.000118	0.000319	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—CDKN1A—urinary bladder cancer	0.000117	0.000318	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—FGFR3—urinary bladder cancer	0.000117	0.000318	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—PTEN—urinary bladder cancer	0.000117	0.000318	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—EP300—urinary bladder cancer	0.000117	0.000317	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—GSTZ1—urinary bladder cancer	0.000116	0.000315	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—CREBBP—urinary bladder cancer	0.000115	0.000311	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—SRC—urinary bladder cancer	0.000113	0.000308	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—IGF1—urinary bladder cancer	0.000113	0.000308	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—EP300—urinary bladder cancer	0.000112	0.000303	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—GSTO2—urinary bladder cancer	0.00011	0.000298	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—NAT1—urinary bladder cancer	0.00011	0.000298	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—SRC—urinary bladder cancer	0.000109	0.000296	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—SRC—urinary bladder cancer	0.000109	0.000295	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—FGFR3—urinary bladder cancer	0.000108	0.000294	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—S100B—urinary bladder cancer	0.000104	0.000283	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—RHOA—urinary bladder cancer	0.000104	0.000282	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—UGT2B7—urinary bladder cancer	0.0001	0.000273	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—CREBBP—urinary bladder cancer	9.98e-05	0.000271	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—EGFR—urinary bladder cancer	9.95e-05	0.00027	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—CDH1—urinary bladder cancer	9.91e-05	0.000269	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—MYC—urinary bladder cancer	9.72e-05	0.000264	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—ERBB2—urinary bladder cancer	9.61e-05	0.000261	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—EGFR—urinary bladder cancer	9.55e-05	0.000259	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—EGFR—urinary bladder cancer	9.51e-05	0.000258	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—KRAS—urinary bladder cancer	9.4e-05	0.000255	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—NCOR1—urinary bladder cancer	9.37e-05	0.000254	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—CREBBP—urinary bladder cancer	9.22e-05	0.00025	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—CXCL8—urinary bladder cancer	9.11e-05	0.000247	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—CYP4B1—urinary bladder cancer	9.05e-05	0.000246	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—KRAS—urinary bladder cancer	9.02e-05	0.000245	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—KRAS—urinary bladder cancer	8.99e-05	0.000244	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—IL2—urinary bladder cancer	8.71e-05	0.000236	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—SLC19A1—urinary bladder cancer	8.54e-05	0.000232	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—CCND1—urinary bladder cancer	8.49e-05	0.00023	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—ERBB2—urinary bladder cancer	8.36e-05	0.000227	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—RHOA—urinary bladder cancer	8.34e-05	0.000226	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—PRSS3—urinary bladder cancer	8.33e-05	0.000226	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—TERT—urinary bladder cancer	8.26e-05	0.000224	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—MMP9—urinary bladder cancer	8.24e-05	0.000224	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—CDKN1A—urinary bladder cancer	8.21e-05	0.000223	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—PTEN—urinary bladder cancer	8.19e-05	0.000222	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—HRAS—urinary bladder cancer	7.99e-05	0.000217	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—EP300—urinary bladder cancer	7.81e-05	0.000212	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—ERBB2—urinary bladder cancer	7.72e-05	0.000209	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—HRAS—urinary bladder cancer	7.67e-05	0.000208	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—HRAS—urinary bladder cancer	7.64e-05	0.000207	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—SRC—urinary bladder cancer	7.6e-05	0.000206	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—FGFR3—urinary bladder cancer	7.58e-05	0.000206	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—IL2—urinary bladder cancer	7.58e-05	0.000206	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—PTGS2—urinary bladder cancer	7.55e-05	0.000205	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—ESR1—urinary bladder cancer	7.36e-05	0.0002	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—CDKN1A—urinary bladder cancer	7.14e-05	0.000194	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—PTEN—urinary bladder cancer	7.13e-05	0.000193	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—MYC—urinary bladder cancer	6.81e-05	0.000185	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—EP300—urinary bladder cancer	6.8e-05	0.000185	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—EGFR—urinary bladder cancer	6.66e-05	0.000181	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—TYMP—urinary bladder cancer	6.66e-05	0.000181	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—SRC—urinary bladder cancer	6.61e-05	0.000179	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—CDKN1A—urinary bladder cancer	6.6e-05	0.000179	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—PTEN—urinary bladder cancer	6.58e-05	0.000179	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—CREBBP—urinary bladder cancer	6.45e-05	0.000175	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—IGF1—urinary bladder cancer	6.37e-05	0.000173	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—KRAS—urinary bladder cancer	6.29e-05	0.000171	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—EP300—urinary bladder cancer	6.28e-05	0.00017	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—SRC—urinary bladder cancer	6.1e-05	0.000166	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—NAT2—urinary bladder cancer	6.02e-05	0.000163	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—RHOA—urinary bladder cancer	5.84e-05	0.000158	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—EGFR—urinary bladder cancer	5.79e-05	0.000157	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—TP53—urinary bladder cancer	5.59e-05	0.000152	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—KRAS—urinary bladder cancer	5.47e-05	0.000149	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—MYC—urinary bladder cancer	5.47e-05	0.000148	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—ERBB2—urinary bladder cancer	5.4e-05	0.000147	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—EGFR—urinary bladder cancer	5.35e-05	0.000145	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—HRAS—urinary bladder cancer	5.35e-05	0.000145	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—RRM2—urinary bladder cancer	5.2e-05	0.000141	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—CXCL8—urinary bladder cancer	5.13e-05	0.000139	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—KRAS—urinary bladder cancer	5.05e-05	0.000137	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—IL2—urinary bladder cancer	4.9e-05	0.000133	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—ENO2—urinary bladder cancer	4.81e-05	0.000131	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—HPGDS—urinary bladder cancer	4.81e-05	0.000131	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—CCND1—urinary bladder cancer	4.77e-05	0.00013	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—GSTT1—urinary bladder cancer	4.67e-05	0.000127	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—HRAS—urinary bladder cancer	4.65e-05	0.000126	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—MMP9—urinary bladder cancer	4.64e-05	0.000126	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—CDKN1A—urinary bladder cancer	4.62e-05	0.000125	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—PTEN—urinary bladder cancer	4.61e-05	0.000125	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—EP300—urinary bladder cancer	4.4e-05	0.000119	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—HRAS—urinary bladder cancer	4.3e-05	0.000117	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—SRC—urinary bladder cancer	4.27e-05	0.000116	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—NQO1—urinary bladder cancer	3.88e-05	0.000105	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—MYC—urinary bladder cancer	3.83e-05	0.000104	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—EGFR—urinary bladder cancer	3.75e-05	0.000102	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—KRAS—urinary bladder cancer	3.54e-05	9.61e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—GSTP1—urinary bladder cancer	3.24e-05	8.78e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—TP53—urinary bladder cancer	3.15e-05	8.54e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—TYMS—urinary bladder cancer	3.01e-05	8.16e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—HRAS—urinary bladder cancer	3.01e-05	8.16e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—GSTM1—urinary bladder cancer	2.97e-05	8.07e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—NCOR1—urinary bladder cancer	2.97e-05	8.07e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—GPX1—urinary bladder cancer	2.85e-05	7.73e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—ERCC2—urinary bladder cancer	2.8e-05	7.59e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—MTHFR—urinary bladder cancer	2.63e-05	7.13e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—PPARG—urinary bladder cancer	2.13e-05	5.78e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—CREBBP—urinary bladder cancer	2.05e-05	5.56e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—PTGS2—urinary bladder cancer	1.68e-05	4.55e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—PTEN—urinary bladder cancer	1.46e-05	3.97e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—EP300—urinary bladder cancer	1.39e-05	3.78e-05	CbGpPWpGaD
